MX2015014668A - Angiotensinas en la distrofia muscular. - Google Patents

Angiotensinas en la distrofia muscular.

Info

Publication number
MX2015014668A
MX2015014668A MX2015014668A MX2015014668A MX2015014668A MX 2015014668 A MX2015014668 A MX 2015014668A MX 2015014668 A MX2015014668 A MX 2015014668A MX 2015014668 A MX2015014668 A MX 2015014668A MX 2015014668 A MX2015014668 A MX 2015014668A
Authority
MX
Mexico
Prior art keywords
angiotensin
muscular dystrophy
peptide
present
lle5
Prior art date
Application number
MX2015014668A
Other languages
English (en)
Spanish (es)
Inventor
Richard Franklin
Sabharwal Rasna
Mark Chapleau
Original Assignee
Univ Iowa Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Iowa Res Found filed Critical Univ Iowa Res Found
Publication of MX2015014668A publication Critical patent/MX2015014668A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
MX2015014668A 2013-04-19 2014-04-18 Angiotensinas en la distrofia muscular. MX2015014668A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361813929P 2013-04-19 2013-04-19
US201361818307P 2013-05-01 2013-05-01
PCT/US2014/034615 WO2014189634A1 (en) 2013-04-19 2014-04-18 Angiotensins in muscular dystrophy

Publications (1)

Publication Number Publication Date
MX2015014668A true MX2015014668A (es) 2016-06-30

Family

ID=51933952

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014668A MX2015014668A (es) 2013-04-19 2014-04-18 Angiotensinas en la distrofia muscular.

Country Status (11)

Country Link
US (2) US20160074464A1 (enExample)
EP (1) EP2986341A4 (enExample)
JP (1) JP2016522178A (enExample)
KR (1) KR20160026855A (enExample)
CN (1) CN105636645A (enExample)
AU (1) AU2014269028A1 (enExample)
BR (1) BR112015026286A2 (enExample)
CA (1) CA2909002A1 (enExample)
MX (1) MX2015014668A (enExample)
RU (1) RU2015141336A (enExample)
WO (1) WO2014189634A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2016152088A (ru) 2014-07-17 2018-08-21 Юниверсити Оф Саузерн Калифорния Способы, соединения и композиции для лечения заболеваний опорно-двигательного аппарата
US10973869B2 (en) 2017-05-17 2021-04-13 Constant Therapeutics Llc Methods of treating cardiomyopathy associated with genetic disorders
SG11202104713RA (en) 2018-11-06 2021-06-29 Edgewise Therapeutics Inc Pyridazinone compounds and uses thereof
CN113272280A (zh) 2018-11-06 2021-08-17 艾知怀斯治疗学公司 哒嗪酮化合物及其用途
DK3877052T3 (da) * 2018-11-06 2023-09-25 Edgewise Therapeutics Inc Pyridazinonforbindelser og anvendelser deraf
CN118680926B (zh) * 2024-07-30 2024-12-20 北京市糖尿病研究所(北京市糖尿病防治办公室) Mas受体激动剂在制备预防或治疗多囊卵巢综合征的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU78601A (sh) * 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
US8575111B2 (en) * 2007-01-26 2013-11-05 Universidade Federal de Minas Garais-UFMG Pharmaceutical compositions and methods for treating erectile dysfunction
EP2163259B1 (en) * 2008-09-12 2012-06-13 Charité-Universitätsmedizin Berlin (Charité) Use of an Ang-(1-7) receptor agonist in acute lung injury
WO2013063280A1 (en) * 2011-10-25 2013-05-02 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
BR132012028005E2 (pt) * 2012-10-31 2014-11-18 Univ Minas Gerais Composições farmacêuticas contendo um agonista do receptor mas para o tratamento de doenças degenerativas musculares.

Also Published As

Publication number Publication date
RU2015141336A (ru) 2017-05-22
CN105636645A (zh) 2016-06-01
KR20160026855A (ko) 2016-03-09
US20180221433A1 (en) 2018-08-09
CA2909002A1 (en) 2014-11-27
US20160074464A1 (en) 2016-03-17
AU2014269028A1 (en) 2015-10-22
WO2014189634A1 (en) 2014-11-27
JP2016522178A (ja) 2016-07-28
EP2986341A1 (en) 2016-02-24
EP2986341A4 (en) 2016-11-30
BR112015026286A2 (pt) 2017-10-10

Similar Documents

Publication Publication Date Title
MX2015014668A (es) Angiotensinas en la distrofia muscular.
NZ713202A (en) Diagnosis and treatments relating to th2 inhibition
NZ602471A (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
MX2019013752A (es) Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones.
NZ623576A (en) Tfpi inhibitors and methods of use
NZ611878A (en) Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
EA201490809A1 (ru) Способы и композиции для лечения неэффективного эритропоэза
FI3442602T3 (fi) Mikrodystrofiinin anto adeno-assioituneella virusvektorilla lihasdystrofian hoitamiseksi
MX357505B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
NZ627372A (en) Clostridium histolyticum enzymes and methods for the use thereof
MX336187B (es) Metodo para tratar el mal de parkinson.
JP2015517488A5 (enExample)
MX366134B (es) Angiotensina en el tratamiento de condiciones cerebrales.
JP2018509388A5 (enExample)
NZ600583A (en) Visfatin therapeutic agents for the treatment of acne and other conditions
PH12014501620A1 (en) Compositions and methods for the treatment of hepatic diseases and disorders
NZ700824A (en) Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
NZ602693A (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
PH12013500559A1 (en) Combination therapy for treating hcv infection
NZ610620A (en) Inhibitors of apoptosis and uses thereof
MX363507B (es) Metodos para administrar óxido nítrico a la sangre arterial o arterializada.
NZ703514A (en) Fviii peptides for immune tolerance induction and immunodiagnostics
MX2015007402A (es) Fusion de hormona de crecimiento humano y albumina, formulacion y usos de los mismos.
WO2014145524A3 (en) Compositions and methods for immune tolerance induction to factor viii replacement therapies in subjects with hemophilia a
NZ590469A (en) Treatment of rheumatoid arthritis with human beta defensins (1-4)